BRAIN Biotech Full Year 2024 Earnings: Misses Expectations

BRAIN Biotech (ETR:BNN) Full Year 2024 Results

Key Financial Results

• Revenue: €56.0m (flat on FY 2023).
• Net loss: €11.1m (loss widened by 34% from FY 2023).
• €0.51 loss per share (further deteriorated from €0.38 loss in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

BRAIN Biotech Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 5.6%. Earnings per share (EPS) also missed analyst estimates by 87%.

Looking ahead, revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany.

Performance of the German Chemicals industry.

The company's shares are down 6.9% from a week ago.

Risk Analysis

You should learn about the 2 warning signs we've spotted with BRAIN Biotech.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.